 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Enrollment open: Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - Mar 5, 2025
P3, N=580, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting
- |||||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
New P3 trial: Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - Feb 13, 2025
P3, N=2320, Not yet recruiting, Sponsor: Sanofi
- |||||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
New P3 trial: Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - Feb 13, 2025
P3, N=580, Not yet recruiting, Sponsor: Sanofi
- | Trial completion: SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - Feb 1, 2024
P1, N=54, Completed, Sponsor: Stanford University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD)
New P4 trial: Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination. (clinicaltrials.gov) - Dec 28, 2023
P4, N=300, Not yet recruiting, Sponsor: Best Healthcare Inc.
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD), Havrix (hepatitis A vaccine, inactivated) / GSK
Journal: Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study. (Pubmed Central) - Jul 20, 2023
The seroprotection against HAV remained high in the long-term follow-up among PLWH on antiretroviral therapy after 2-dose HAV vaccination. Regular monitoring of seroresponses and timely administration of HAV vaccines are warranted to maintain seroprotection.
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD), Aimmugen (freeze-dried inactivated tissue culture hepatitis A vaccine) / Astellas, Meiji Seika, Mitsubishi Tanabe, Havrix (hepatitis A vaccine, inactivated) / GSK
Journal: Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults. (Pubmed Central) - Jul 14, 2023
Registered 03 April 2014. https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000015906.
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD)
Yikes. Our vaqta boxes don't come with needles, just the prefilled syringe (Twitter) - Jul 14, 2023
- | Trial completion date, Trial primary completion date: SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - Apr 18, 2023
P1, N=54, Active, not recruiting, Sponsor: Stanford University
https://center6.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000015906. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date: Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients (clinicaltrials.gov) - Jan 26, 2023
P4, N=153, Completed, Sponsor: National Taiwan University Hospital
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Completed | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2022
- | Phase classification: SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - Dec 14, 2022
P1, N=54, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Completed | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2022 Phase classification: P4 --> P1
- | Trial completion: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Oct 29, 2021
P=N/A, N=55, Completed, Sponsor: Wake Forest University Health Sciences
Phase classification: P4 --> P1 Active, not recruiting --> Completed
- | Trial completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Aug 18, 2021
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed Trial completion date: Jul 2021 --> Oct 2021
- ||||||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial completion: PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) - Jun 2, 2021
P3, N=1720, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jul 2021 --> Oct 2021 Active, not recruiting --> Completed
- | Trial completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Apr 29, 2021
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed Trial completion date: Apr 2021 --> Jul 2021
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD)
Trial completion date, Trial primary completion date: Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients (clinicaltrials.gov) - Mar 16, 2021
P4, N=170, Recruiting, Sponsor: National Taiwan University Hospital
Trial completion date: Apr 2021 --> Jul 2021 Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2019 --> Sep 2021
- | Trial completion date, Trial primary completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Dec 19, 2020
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Sep 2020 --> Sep 2022 | Trial primary completion date: Sep 2019 --> Sep 2021 Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Apr 2019 --> Jan 2020
- | Trial completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Oct 1, 2020
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Apr 2019 --> Jan 2020 Trial completion date: Sep 2020 --> Dec 2020
- | Trial completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Jul 24, 2020
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Sep 2020 --> Dec 2020 Trial completion date: Jun 2020 --> Sep 2020
- | Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial primary completion date: PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) - Feb 24, 2020
P3, N=1720, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2020 --> Sep 2020 Trial primary completion date: Dec 2020 --> May 2021
- | Trial completion date, Trial primary completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Jan 27, 2020
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Dec 2020 --> May 2021 Trial completion date: Feb 2021 --> Apr 2020 | Trial primary completion date: Feb 2020 --> Apr 2019
- | Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment closed: PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) - Jan 13, 2020
P3, N=1720, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Feb 2021 --> Apr 2020 | Trial primary completion date: Feb 2020 --> Apr 2019 Recruiting --> Active, not recruiting
- | Enrollment closed, Trial completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Oct 15, 2019
P=N/A, N=55, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Feb 2020 --> Feb 2021
- | Trial completion date, Trial primary completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Sep 26, 2019
P=N/A, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting | Trial completion date: Feb 2020 --> Feb 2021 Trial completion date: Sep 2019 --> Feb 2020 | Trial primary completion date: Sep 2019 --> Dec 2019
- | Phase classification: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Sep 23, 2019
P=N/A, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Sep 2019 --> Feb 2020 | Trial primary completion date: Sep 2019 --> Dec 2019 Phase classification: P2 --> P=N/A
- | Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment open: PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) - Jun 27, 2019
P3, N=1720, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P=N/A Not yet recruiting --> Recruiting
- | Enrollment closed, Trial completion date, Trial primary completion date: SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - Apr 5, 2019
P4, N=54, Active, not recruiting, Sponsor: Stanford University
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | Trial completion date: Aug 2023 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
- | Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P3 trial: PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) - Mar 28, 2019
P3, N=1720, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD), ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Phase classification: Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) (clinicaltrials.gov) - Feb 4, 2019
P4, N=1800, Completed, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Active, not recruiting | Trial completion date: Aug 2023 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022 Phase classification: P3 --> P4
- | Trial completion date, Trial primary completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Dec 28, 2018
P2, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Phase classification: P3 --> P4 Trial completion date: Jan 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019
- | Trial completion date, Trial primary completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Jul 27, 2018
P2, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Jan 2019 --> Jul 2019 | Trial primary completion date: Jan 2019 --> Jul 2019 Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018
- | Phase classification: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Apr 13, 2018
P2, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018 Phase classification: P=N/A --> P2
- | New P4 trial: SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - Oct 18, 2017
P4, N=60, Enrolling by invitation, Sponsor: Stanford University
- | Trial primary completion date: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Aug 17, 2017
P=N/A, N=50, Recruiting, Sponsor: Wake Forest University Health Sciences
Phase classification: P=N/A --> P2 Trial primary completion date: May 2017 --> Aug 2018
- ||| PRV-3279 / Sanofi
Trial completion: Phase 1 Study of MGD010 in Healthy Subjects (clinicaltrials.gov) - Mar 29, 2017
P1, N=73, Completed, Sponsor: MacroGenics
Trial primary completion date: May 2017 --> Aug 2018 Active, not recruiting --> Completed
- || PRV-3279 / Sanofi
Enrollment closed, Trial primary completion date: Phase 1 Study of MGD010 in Healthy Subjects (clinicaltrials.gov) - Jan 12, 2017
P1, N=73, Active, not recruiting, Sponsor: MacroGenics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Feb 2017
- || PRV-3279 / Sanofi
Enrollment change: Phase 1 Study of MGD010 in Healthy Subjects (clinicaltrials.gov) - Jul 19, 2016
P1, N=73, Recruiting, Sponsor: MacroGenics
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Feb 2017 N=48 --> 73
- Enrollment open: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - May 31, 2016
P=N/A, N=50, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=48 --> 73 Not yet recruiting --> Recruiting
- New trial: Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- PRV-3279 / Sanofi
Trial primary completion date: Phase 1 Study of MGD010 in Healthy Subjects (clinicaltrials.gov) - Mar 16, 2016
P1, N=48, Recruiting, Sponsor: MacroGenics
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Sep 2016
- Isentress (raltegravir) / Merck (MSD)
Trial withdrawal, Trial primary completion date: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Apr 14, 2015
P3, N=0, Withdrawn, Sponsor: McGill University Health Center
Trial primary completion date: Jan 2016 --> Sep 2016 Terminated --> Withdrawn | Trial primary completion date: Dec 2012 --> Aug 2011
- | PRV-3279 / Sanofi
New P1 trial: Phase 1 Study of MGD010 in Healthy Subjects (clinicaltrials.gov) - Mar 3, 2015
P1, N=48, Recruiting, Sponsor: MacroGenics
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD), ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Phase classification: Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) (clinicaltrials.gov) - Dec 5, 2014
P4, N=653, Completed, Sponsor: Merck Sharp & Dohme Corp.
Terminated --> Withdrawn | Trial primary completion date: Dec 2012 --> Aug 2011 Phase classification: P3 --> P4
- ||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Enrollment change, Head-to-Head: Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults (clinicaltrials.gov) - Dec 1, 2011
P4, N=213, Completed, Sponsor: GlaxoSmithKline
Phase classification: P3 --> P4 N=495 --> 213
- Isentress (raltegravir) / Merck (MSD)
Trial termination: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Sep 26, 2011
P3, N=0, Terminated, Sponsor: McGill University Health Center
N=495 --> 213 Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment.
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Sep 26, 2011
P3, N=0, Terminated, Sponsor: McGill University Health Center
Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment. N=60 --> 0